Related Experiment Video
Updated: Jun 23, 2025

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Generative AI for precision neuroimaging biomarker development in psychiatry
Susan N Wright1, Alan Anticevic2
1Division of Neuroscience and Behavior, National Institute on Drug Abuse, National Institutes of Health, 11601 Landsdown St., Three White Flint North (3WFN), MSC 6018, Rockville, MD 20852, United States.
Abstract:
The explosion of generative AI offers promise for neuroimaging biomarker development in psychiatry, but effective adoption of AI methods requires clarity with respect to specific applications and challenges. These center on dataset sizes required to robustly train AI models along with feature selection that capture neural signals relevant to symptom and treatment targets. Here we discuss areas where generative AI could improve quantification of robust and reproducible brain-to-symptom associations to inform precision psychiatry applications, especially in the context of drug discovery. Finally, this communication discusses some challenges that need solutions for generative AI models to advance neuroimaging biomarkers in psychiatry.

